Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tirbanibulin Mesylate (KX01 Mesylate) 是一种 Src 抑制剂,靶向 Src 的肽底物位点。在肿瘤细胞中,GI50值为 9-60 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 233 | 现货 | ||
2 mg | ¥ 329 | 现货 | ||
5 mg | ¥ 523 | 现货 | ||
10 mg | ¥ 652 | 现货 | ||
25 mg | ¥ 1,330 | 现货 | ||
50 mg | ¥ 2,570 | 现货 | ||
100 mg | ¥ 4,390 | 现货 | ||
200 mg | ¥ 6,220 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 622 | 现货 |
产品描述 | Tirbanibulin Mesylate (KX01 Mesylate) is an inhibitor of Src that targets the peptide substrate site of Src (GI50: 9-60 nM in cancer cell lines). |
靶点活性 | Src:13 nM(in PLC/PRF/5 cells), Src:26 nM(in Hep3B cells), Src:60 nM(in HepG2 cells), Src:9 nM (GI50, in HuH7 cells) |
体外活性 | Tirbanibulin Mesylate is found to inhibit certain leukemia cells that are resistant to current commercially available drugs, such as those derived from chronic leukemia cells with the T3151 mutation. Tirbanibulin Mesylate displays steep dose-response curves against Huh7 (GI50=9 nM), PLC/PRF/5 (GI50=13 nM), Hep3B (GI50=26 nM), and HepG2 (GI50=60 nM), four hepatic cell cancer (HCC) cell lines [1]. Tirbanibulin Mesylate is evaluated in engineered Src drove cell growth assays inNIH3T3/c-Src527F and SYF/c-Src527F cells and exhibits GI50 with 23 nM and 39 nM, respectively [2]. |
体内活性 | In pre-clinical animal models of cancer, Tirbanibulin Mesylate (p.o.) is shown to inhibit primary tumor growth and to suppress metastasis [2]. |
别名 | KX2-391 Mesylate, KX01 Mesylate |
分子量 | 527.63 |
分子式 | C27H33N3O6S |
CAS No. | 1080645-95-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 99 mg/mL (187.63 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.8953 mL | 9.4763 mL | 18.9527 mL | 47.3817 mL |
5 mM | 0.3791 mL | 1.8953 mL | 3.7905 mL | 9.4763 mL | |
10 mM | 0.1895 mL | 0.9476 mL | 1.8953 mL | 4.7382 mL | |
20 mM | 0.0948 mL | 0.4738 mL | 0.9476 mL | 2.3691 mL | |
50 mM | 0.0379 mL | 0.1895 mL | 0.3791 mL | 0.9476 mL | |
100 mM | 0.019 mL | 0.0948 mL | 0.1895 mL | 0.4738 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Tirbanibulin Mesylate 1080645-95-9 Angiogenesis Cytoskeletal Signaling Tyrosine Kinase/Adaptors Microtubule Associated Src KX01 KX-01 Mesylate KX2-391 KX 01 Mesylate Inhibitor KX2-391 Mesylate inhibit KX-01 Tirbanibulin KX 01 Microtubule/Tubulin KX01 Mesylate inhibitor